BRISBANE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on November 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of
TRUTAKNA® (atacicept-vymj) U.S. launch building early momentum following July 7 accelerated approval by the U.S. Food and Drug Administration (FDA) with approximately 700 Patient Start Forms (PSFs) to date and $10.3
BRISBANE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a commercial-stage biotechnology company, today announced that the Company’s management team will participate in a fireside
TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, achieved statistical significance in all prespecified endpoints, including eGFR change from baseline and annualized slope, and risk reduction in
Investor webcast at 4:30 p.m. ET on October 22 to discuss ORIGIN 3 final efficacy results for TRUTAKNA™ (atacicept-vymj) featured in a late-breaking oral presentation during the opening plenary session of ASN Kidney
BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on September 29, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of
BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a commercial-stage biotechnology company, today announced that there will be multiple presentations at the American Society of
TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite kidney disease
BRISBANE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on September 1, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of
BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a commercial-stage biotechnology company, today announced that the Company’s management team will present and participate in
TRUTAKNA™ granted accelerated approval by U.S. Food and Drug Administration (FDA) in adult patients with primary IgA nephropathy (IgAN) at risk for disease progression.Alignment with FDA on earlier ORIGIN 3 final
BRISBANE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on August 3, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera
BRISBANE, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on July 6, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera
BRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Officer position.
TRUTAKNA is the first and only available therapy that binds both B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), addressing the immunological drivers at the source of IgA nephropathy
